Exploring Overall Survival Benefit In Elderly Patients With Cll Treated With First Line Ibrutinib
Exploring Overall Survival Benefit In Elderly Patients With Cll Treated With First Line Ibrutinib reveals several interesting facts.
- Dr Tedeschi talks to ecancertv at ASH 2015 about using
- Ibrutinib
- Matthew Davids, MD, MMSc, an associate director with the Center for
- Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd,
- Paul Barr, MD of the University of Rochester discusses recent data presented at the 58th Annual ASH Meeting & Exposition ...
In-Depth Information on Overall Survival Benefit In Elderly Patients With Cll Treated With First Line Ibrutinib
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, shares the results of a study that showed improved Alessandra Tedeschi MD, Department of Hematology, Azienda Ospedaliera Niguarda Ca' Granda in Milan, Italy, discusses the ... Sameer Parikh, MBBS, explains the challenges in Targeted therapies have greatly improved
The CAPTIVATE study results support using
Stay tuned for more updates related to Overall Survival Benefit In Elderly Patients With Cll Treated With First Line Ibrutinib.